Enanta Pharmaceuticals (ENTA) EBIAT (2016 - 2025)
Enanta Pharmaceuticals (ENTA) has disclosed EBIAT for 14 consecutive years, with -$11.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT rose 46.44% year-over-year to -$11.9 million, compared with a TTM value of -$71.5 million through Dec 2025, up 31.82%, and an annual FY2025 reading of -$81.9 million, up 29.43% over the prior year.
- EBIAT was -$11.9 million for Q4 2025 at Enanta Pharmaceuticals, up from -$18.7 million in the prior quarter.
- Across five years, EBIAT topped out at -$11.9 million in Q4 2025 and bottomed at -$39.1 million in Q2 2023.
- Average EBIAT over 5 years is -$26.8 million, with a median of -$27.2 million recorded in 2022.
- The sharpest move saw EBIAT plummeted 267.11% in 2021, then skyrocketed 46.44% in 2025.
- Year by year, EBIAT stood at -$30.1 million in 2021, then increased by 3.75% to -$29.0 million in 2022, then dropped by 15.25% to -$33.4 million in 2023, then skyrocketed by 33.28% to -$22.3 million in 2024, then skyrocketed by 46.44% to -$11.9 million in 2025.
- Business Quant data shows EBIAT for ENTA at -$11.9 million in Q4 2025, -$18.7 million in Q3 2025, and -$18.3 million in Q2 2025.